Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model

Reproductive Sciences

Volumn 18, Issue 1, 2011, Pages 57-63

  Van Calsteren, Kristel ^a   Verbesselt, Rene ^a   Van Bree, Rieta ^a   Heyns, Liesbeth ^a   De Bruijn, Ernst ^a   De Hoon, Jan ^a   Amant, Frédéric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Mouse; Pharmacokinetics; Pregnancy; Transplacental transport

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTARABINE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; VINBLASTINE;

ANIMAL EXPERIMENT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; FETUS; FETUS BLOOD; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MATERNAL BLOOD; MOUSE; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CYTARABINE; DOXORUBICIN; EPIRUBICIN; FEMALE; FETAL BLOOD; GESTATIONAL AGE; INJECTIONS, INTRAVENOUS; MATERNAL-FETAL EXCHANGE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; PACLITAXEL; PLACENTA; PREGNANCY; VINBLASTINE;

EID: 78149357100     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719110379650     Document Type: Article

References (46)

1. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol. 2009;27(1):45-51.
2. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010;16(1):76-82.
3. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283-291. (Pubitemid 38541580)
4. Wiebe VJ, Sipila PE. Pharmacology of antineoplastic agents in pregnancy. Crit Rev Oncol Hematol. 1994;16(2):75-112. (Pubitemid 24199116)
5. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28(4):683-689.
6. Amant F, Van Calsteren K, Halaska MJ, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer. 2009;19(suppl 1):S1-S12.
7. Liao C, Wei J, Li Q, Li L, Li J, Li D. Efficacy and safety of cordocentesis for prenatal diagnosis. Int J Gynaecol Obstet. 2006;93(1):13-17.
8. Von Tungeln LS, Williams LD, Doerge DR, et al. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. Environ Mol Mutagen. 2007;48(3-4):258-269. (Pubitemid 46536094)
9. Theiler K. The House Mouse: Atlas of Embryonic Development. New York: Springer-Verlag; 1989.
10. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs. 1996;7(1):78-86. (Pubitemid 26059949)
11. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst. 1996;88(14):994-999. (Pubitemid 26239388)
12. Dawrant MJ, Giles S, Bannigan J, Puri P. Adriamycin produces a reproducible teratogenic model of vertebral, anal, cardiovascular, tracheal, esophageal, renal, and limb anomalies in the mouse. J Pediatr Surg. 2007;42(10):1652-1658. (Pubitemid 47513123)
13. Scheving LE, Scheving LA, Feuers RJ, Tsai TH, Cope FO. Chronobiology as it relates to toxicology, pharmacology, and chemotherapy. Regul Toxicol Pharmacol. 1993;17(2 pt 1):209-218.
14. Boughattas NA, Levi F, Fournier C, et al. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J Pharmacol Exp Ther. 1990;255(2):672-679.
15. Collins JM. Inter-species differences in drug properties. Chem Biol Interact. 2001;134(3):237-242. (Pubitemid 32406146)
16. Goldsmith MA, Slavik M, Carter SK. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res. 1975;35(5):1354-1364.
17. De Vita VJ, Hellman S, Rosenberg S. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
18. Gaillard B, Leng JJ, Grellet J, Ducint D, Saux MC. [Transplacental passage of epirubicin]. J Gynecol Obstet Biol Reprod (Paris). 1995;24(1):63-68.
19. Grohard P, Akbaraly JP, Saux MC, et al. [Transplacental passage of doxorubicin]. J Gynecol Obstet Biol Reprod (Paris). 1989;18(5):595-600.
20. Roboz J, Gleicher N, Wu K, Chanihian P, Kerenyi T, Holland J. Does doxorubicin cross the placenta? Lancet. 1979;2(8156-8157):1382-1383.
21. D'Incalci M, Broggini M, Buscaglia M, Pardi G. Transplacental passage of doxorubicin. Lancet. 1983;1(8314-8315):75. (Pubitemid 13211305)
22. Karp GI, von Oeyen P, Valone F, et al. Doxorubicin in pregnancy: possible transplacental passage. Cancer Treat Rep. 1983;67(9):773-777. (Pubitemid 13007280)
23. Murray CL, Reichert JA, Anderson J, Twiggs LB. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. JAMA. 1984;252(18):2607-2608.
24. Barni S, Ardizzoia A, Zanetta G, Strocchi E, Lissoni P, Tancini G. Weekly doxorubicin chemotherapy for breast cancer in pregnancy. A case report. Tumori. 1992;78(5):349-350.
25. Al-Saleh E, Nandakumaran M, Al-Rashdan I, Al-Harmi J, Al-Shammari M. Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. J Matern Fetal Neonatal Med. 2007;20(9):695-701. (Pubitemid 47262699)
26. Al-Saleh E, Al-Harmi J, Nandakumaran M, Al-Shammari M. Transport kinetics of cisplatin in the perfused human placental lobule in vitro. J Matern Fetal Neonatal Med. 2008;21(10):726-731.
27. Henderson CE, Elia G, Garfinkel D, Poirier MC, Shamkhani H, Runowicz CD. Platinum chemotherapy during pregnancy for serous cystadenocarcinoma of the ovary. Gynecol Oncol. 1993;49(1):92-94. (Pubitemid 23148589)
28. Koc ON, McFee M, Reed E, Gerson SL. Detection of platinum- DNA adducts in cord blood lymphocytes following in utero platinum exposure. Eur J Cancer. 1994;30A(5):716-717. (Pubitemid 24164268)
29. Elit L, Bocking A, Kenyon C, Natale R. An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Gynecol Oncol. 1999;72(1):123-127. (Pubitemid 29045462)
30. Arango HA, Kalter CS, Decesare SL, Fiorica JV, Lyman GH, Spellacy WN.Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. Obstet Gynecol. 1994;84(4 pt 2):665-668. (Pubitemid 24308870)
31. Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol. 2004;15(1):146-150. (Pubitemid 38139617)
32. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43(8):487-514. (Pubitemid 38858303)
33. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9(suppl 2):3-8. (Pubitemid 38747838)
34. Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997;15(5):1906-1915. (Pubitemid 27209520)
35. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest. 1999;104(10):1441-1447.
36. Mir O, Berveiller P, Goffinet F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol. 2010;21(2):425-426.
37. Chun KC, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports. Jpn J Clin Oncol. 2010;40(7):694-698.
38. Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34(4):302-312.
39. Peccatori FA, Azim HA Jr, Scarfone G, et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat. 2009;115(3):591-594.
40. Kopf-Maier P. Stage of pregnancy-dependent transplacental passage of 195mPt after cis-platinum treatment. Eur J Cancer Clin Oncol. 1983;19(4):533-536.
41. Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F. Use of platinum derivatives during pregnancy. Cancer. 2008;113(11):3069-3074.
42. Mihaly GW, Morgan DJ. Placental drug transfer: effects of gestational age and species. Pharmacol Ther. 1983;23(2):253-266. (Pubitemid 14184961)
43. Sastry BV. Techniques to study human placental transport. Adv Drug Deliv Rev. 1999;38(1):17-39. (Pubitemid 29216951)
44. Ala-Kokko TI, Myllynen P, Vähäkangas K. Ex vivo perfusion of the human placental cotyledon: implications for anesthetic pharmacology. Int J Obstet Anesth. 2000;9:26-38.
45. Myllynen P, Vahakangas K. An examination of whether human placental perfusion allows accurate prediction of placental drug transport: studies with diazepam. J Pharmacol Toxicol Methods. 2002;48(3):131-138. (Pubitemid 38373494)
46. Van Calsteren K, Devlieger R, De Catte L, et al. Feasibility of ultrasound-guided percutaneous samplings in the pregnant baboon: a model for studies on transplacental transport. Reprod Sci. 2009;16(3):280-285.